While it’s trite to say that the future is unpredictable, the stocks with the most long-term success will, undeniably, track companies that prove adept at anticipating demand in their target markets.
This article is disseminated in partnership with long-term stocks bioAffinity Technologies Inc. and Supermarket Income REIT plc. It is intended to inform investors and should not be taken as a recommendation or financial advice.
Investors unacquainted with crystal balls or reading tea leaves need not worry, however, as these methods are no match for good ol’ fundamental analysis, where a combination of product/service utility and business health offers a far more reliable gauge for incremental shareholder value.
In the latest edition of Weekly Market Movers, I’ll show you exactly what I mean by profiling two stocks whose underlying companies are executing on long-term plans to shape the futures they’re striving towards.
bioAffinity Technologies
bioAffinity Technologies, market cap US$4.23 million, is innovating in early-stage cancer diagnosis to maximize a patient’s probability of safeguarding their quality of life.
The company specializes in the lungs, addressing the difficulty, high costs and often invasive procedures required to assess pulmonary nodules with CyPath Lung, a test that uses flow cytometry (a technique to number and classify cells) and proprietary AI to isolate cells in sputum with the potential for malignancy.
CyPath relies on a fluorescent porphyrin known as TCPP, which is preferentially absorbed by cancer and cancer-related cells. Porphyrins are chemicals needed to make heme, part of hemoglobin, an oxygen-transporting protein in red blood cells.
Results to date indicate 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer with nodules measuring less than 20 millimeters, supporting CyPath’s potential to more promptly identify the need for treatment and increase patient survival rates.
bioAffinity subsidiary Precision Pathology Laboratory Services is currently marketing the product as a Laboratory Developed Test. LDTs, in turn, are overseen by Medicare & Medicaid under the Clinical Laboratory Improvement Amendments.
Down the line, bioAffinity is working to expand its product portfolio with sputum-based tests to detect asthma, as well as predict the effectiveness of new treatments for asthma and Chronic Obstructive Pulmonary Disease, through novel combinations of AI and flow cytometry.
Topical treatments for cutaneous malignancies and neoplasms of the skin are also being developed by third parties based on what bioAffinity has established about how TCPP gains entry into cancer cells. The company’s central, potentially life-changing discovery to date is that suppressing certain cell membrane receptors in lung, breast, skin and brain cancer cells can destroy them without harming healthy ones.
bioAffinity’s value-added developments are backed by a US$4 million capital raise closed in August, to be allocated across commercialization, clinical development and general corporate purposes, under the watchful eye of a veteran leadership team highlighted by:
- Maria Zannes, President and Chief Executive Officer (CEO), whose more than 30 years in executive leadership span the healthcare, energy, and environmental sectors.
- William Bauta, Chief Science Officer, a medicinal chemist of more than 25 years focused on drug discovery and development, including a deep familiarly with the US FDA approvals process.
- Gordon Downie, Chief Medical Officer, whose more than 30 years in pulmonary medicine has seen him lead numerous lung nodule and interventional pulmonology programs.
bioAffinity stock (NASDAQ:BIAF) last traded at US$7.93 and has given back 84.50% year-over-year.
Zannes spoke with Ricki Lee about the company’s growth plans for CyPath Lung. Watch the interview here.
Supermarket Income REIT
Supermarket Income REIT, market cap £1.14 billion, active worlds apart from clinical trials in the grocery sector, is nevertheless kin to bioAffinity in its attempt to keep its target market pointed where the global industrial complex is headed.
The company holds a 131-store portfolio in Western Europe and the United Kingdom valued at more than £2 billion as of June 2026, including household names Tesco, Sainsbury’s, Aldi and Carrefour.
In the company’s estimation, the grocery industry is on a long-term uptrend driven by inflation and population growth, and the best assets to capitalize on that future are omnichannel stores, which are built to handle distribution for online businesses, click and collect grocery programs, as well as in-store shopping, reinforcing the legacy model with more scale and flexible capacity to better thrive in the digital world.
From an operator’s perspective, this multifaceted approach leaves ample room for rapidly growing online grocery demand to contribute to revenue. From a customer’s perspective, higher turnover from accommodating online sales means higher-quality produce on display and more staff on the floor assembling these orders to help in-store shoppers.
The REIT pairs its thesis about the future of grocery with an acquisition framework built on sound fundamentals, including:
- A multi-year track record of growing income.
- Strategic locations near population centers and major transportation networks.
- Tenants with durable positions in the grocery sector.
- Long-dated, inflation-linked leases targeting an average of 15 years.
Financially, this strategy has resulted in annual passing rent growing from £57.8 million in 2021 to £100.62 million in 2025, while maintaining positive and stable earnings per share and a reasonable loan-to-value no higher than 37% over the period, as well as a dividend that has increased every year since the company’s initial public offering in 2017.
Looking ahead, Supermarket Income REIT intends to keep monitoring the grocery industry market for mispriced acquisitions, opportunistic sales and joint venture opportunities through which to foster shareholder value.
Nick Hewson, the REIT’s Chair since inception, and Rob Abraham, who has been steering the ship as CEO since March 2025, bring billions in transactions and more than 50 years of real estate, finance and investing experience to this task, supported by a decorated team that knows how to build value in the capital markets.
Supermarket Income REIT (LSE:SUPR) last traded at £83.60, adding 9% year-over-year, while giving back 30.19% since 2021.
Thanks for reading! I’ll see you next Monday for a new edition of Weekly Market Movers, where I delve into companies that joined Stockhouse for an interview over the past week. Here’s the most recent article, 2 African mining stocks priced well below their potential, in case you missed it.
Join the discussion: Find out what investors are saying about these long-term stocks on the bioAffinity Technologies Inc. Bullboard on Stockhouse and Supermarket Income REIT plc discussion thread on ADVFN.
